Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Coronary Syndrome
EARLY ACS trial designed to reinforce benefit of early use of Integrilin
July 25th, 2005
Millennium Pharmaceuticals, Inc., (MLNM) announced publication of the EARLY ACS (acute coronary syndromes) trial design and rationale in a major journal. The EARLY ACS trial design incorporates new technologies and reflects current treatment patterns in patients with non-ST elevation acute coronary syndromes (nSTE ACS) in a "real-world" setting. nSTE ACS is the term applied to unstable angina and non-ST elevation myocardial infarction (MI). The trial is designed to provide important evidence regarding the potential benefit of initiating Integrilin, a potent glycoprotein (GP) IIb-IIIa inhibitor, early after patients present with high-risk acute...
Source: Health & Medicine Week (2005-07-25)
|
